Biocon Limited is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from 'Lab to Market'. Some of its key brands are INSUGEN® (rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab). It has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, a high potential oral prandial insulin.

**A Credible Biopharma Enterprise:**

- **1200+** patent application filed globally*
- **1069** Patents granted*
- **577** Trademark Registrations*
- **7** Biologics including **2** Novels and **5** Biosimilars taken from Lab to Market
- Key Brands : Insugen®, BASALOG®, ALZUMAb™, BIOMAb EGFR®, CANMAb™, ERYPRO™, BLISTO®, STATIX®, TACROGRAF™, Cytosorb™, Cimivir™
- ~120 countries where our products are available
- **25+** cGMP approvals from international regulatory agencies*
- Key regulatory approvals from US, EU, Japan, France, Brazil, Mexico, Turkey, GCC etc.

*As of 31 March 2017*
Industry Leadership:

- India’s first publicly listed biotech company.
- Developed and launched India’s first Novel Biologic, BIOMAb-EGFR®, for head and neck cancer.
- Developed novel first-in-class anti-CD6 humanized monoclonal antibody, Itolizumab, which has been launched as ALZUMAb™ for the treatment of chronic plaque psoriasis in India.
- CANMAb™, launched in India in 2014, is the first follow-on biologic Trastuzumab to be approved anywhere in the world.
- Biocon’s Insulin Glargine, a long-acting insulin analog, is the first biosimilar from India to be approved and launched in Japan.
- Biocon is the largest Asian insulins player and the fourth largest producer of insulins in the world.
- Biocon is the world’s largest statins manufacturer; its drug substance is being used to produce ‘one in every three’ statin pills globally.
- Biocon is developing Insulin Tregopil, a novel ‘first-in-class’ oral prandial insulin.
- Among the highest R&D spenders in India.

Growth Verticals: Aligned with Shifting Paradigms

![Growth Verticals Diagram]

For more information contact:

Seema Ahuja
VP & Global Head of Communications
T: +91-80-2808-2222
Email: seema.ahuja@biocon.com